Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AFX01-11: A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Peginesatide for the Correction of Anemia in Patients With Chronic Renal Failure (CRF) Not on Dialysis and Not on Erythropoiesis Stimulating Agent (ESA) Treatment

NCT00598273 is registered in ClinicalTrials.gov with Affymax as lead sponsor.

NCT NCT00598273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00598273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AFX01-11: A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Peginesatide for the Correction of Anemia in Patients With Chronic Renal Failure (CRF) Not on Dialysis and Not on Erythropoiesis Stimulating Agent (ESA) Treatment
Lead sponsor
Affymax
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2007
Completion date
February 28, 2010
Enrollment
490 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, chronic kidney disease, chronic renal failure